Talcum Powder lawsuit update

Verified snapshot

The facts that anchor this dossier

The largest active federal MDL combines old product-use histories, contested ovarian-cancer and mesothelioma theories, evolving asbestos-testing policy, and years of bankruptcy detours. This is the evidence-first version without a settlement calculator.

Federal proceeding

MDL 2738

District of New Jersey before Judge Michael A. Shipp.

Pending federal actions

68,914

JPML count as of August 3, 2026. This is the largest active federal MDL by pending actions.

Historical actions

71,601

Federal MDL total through August 3, 2026. State-court litigation is counted separately.

Core alleged injuries

Ovarian cancer and mesothelioma

The two categories differ in disease theory, exposure route, and evidence. Analyze them separately.

FDA 2023 sample result

0 of 50 detected asbestos

A targeted market sample, not proof about every talc product, mine, lot, or historical period.

Documented chronology

How the litigation reached this point

What the ovarian-cancer and mesothelioma claims each allege

MDL 2738 is usually called the talcum-powder case. That shorthand covers two materially different theories. Ovarian-cancer actions commonly allege repeated perineal use and a biological movement or inflammatory mechanism. Mesothelioma actions focus on alleged asbestos contamination and inhalation. The underlying facts diverge as well: product formulation, exposure route, and latency period all differ between the two groups. A headline about one disease does not transfer to the other.

The JPML centralized recurring pretrial issues. It made no finding that talc caused cancer or that any product contained asbestos. The District of New Jersey currently identifies Judge Michael A. Shipp and Magistrate Judge Rukhsanah L. Singh as presiding judges. At 68,914 pending actions in the current report, MDL 2738 is the largest active MDL by pending count. Size measures administrative volume, not the strength or value of any particular claim.

What the ovarian-cancer studies found

Case-control studies have often reported modest associations between genital talc use and ovarian cancer. Prospective cohorts have generally been less supportive. A 2020 pooled analysis combined 252,745 women from four U.S. cohorts and found no statistically significant association between genital powder use and incident ovarian cancer, while cautioning that the study might have been underpowered to detect a small increase. Results split along study design, which is why any single relative-risk number misleads.

Recall bias can affect case-control research because people are asked to reconstruct use after diagnosis. Cohort studies reduce that problem by recording exposure before disease but may still misclassify product composition, frequency, location of use, or changes over decades. Epidemiology estimates population patterns; it does not identify fibers in a person's tissue, establish the contents of a historical product lot, or prove specific causation.

How FDA tests talc for asbestos

FDA describes talc and asbestos as distinct naturally occurring minerals that can form near one another. Asbestos is a known carcinogen when inhaled, which puts contamination control and testing at the center of the mesothelioma claims. In the agency's 2023 sampling assignment, polarized-light and transmission-electron microscopy found no asbestos in 50 selected talc-containing cosmetic samples. That result covers the samples tested. It certifies no brand, historical lot, or mining source beyond them.

Later regulatory activity shows where the limits sit. In 2024, an FDA-posted recall covered specified Dynarex baby powder lots after routine sampling found asbestos. FDA proposed standardized testing methods in December 2024, then withdrew the proposal in November 2025 because the comments warranted further assessment. A withdrawal returns the question to the agency. It is not a safety finding in either direction.

What the Red River bankruptcy decided

Corporate restructuring repeatedly interrupted the path of talc litigation. The 2024 Red River Talc Chapter 11 sought an aggregate bankruptcy route for ovarian and gynecological cancer claims. In March 2025, the bankruptcy court denied confirmation and dismissed the case. Separate federal court materials later discussed voting and solicitation concerns arising from that proceeding.

A bankruptcy dismissal changes the forum and the proposed resolution mechanism. It reaches no verdict on whether talc caused any claimant's disease and sets no value for the MDL. The federal docket remains listed as active while numerous state-court proceedings follow their own tracks. Bankruptcy orders, MDL case-management orders, and state verdicts each answer a different legal question, so an update about one says nothing certain about the others.

The records that reconstruct an individual exposure history

Long latency and changing product formulations make contemporaneous records valuable. Three kinds carry the most weight: product and purchase evidence, a use history covering location and approximate years, and the pathology and oncology file. Mesothelioma work also investigates other occupational or household asbestos sources. Ovarian-cancer work brings histology, reproductive history, and other risk factors into the analysis.

None of that converts into a public payout estimate. Limitation rules vary by state, defendants and products differ, and pending motions can change which theories remain viable. The JPML count covers federal actions assigned to the MDL and omits state cases, and it does not indicate how many actions will be tried, dismissed, or remanded. This dossier reports the process and the evidence, and stops there.

Reader questions

Frequently asked questions